Histogen Inc. (NASDAQ:HSTO) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 506,800 shares, a growth of 174.5% from the December 15th total of 184,600 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average trading volume of 623,000 shares, the short-interest ratio is presently 0.8 days.
Several hedge funds have recently added to or reduced their stakes in the company. Two Sigma Securities LLC grew its stake in shares of Histogen by 124.7% in the 3rd quarter. Two Sigma Securities LLC now owns 52,289 shares of the company’s stock valued at $40,000 after purchasing an additional 29,019 shares during the period. Geode Capital Management LLC grew its position in Histogen by 20.0% during the 3rd quarter. Geode Capital Management LLC now owns 207,892 shares of the company’s stock worth $157,000 after acquiring an additional 34,649 shares during the last quarter. Newman Dignan & Sheerar Inc. bought a new stake in Histogen during the 3rd quarter worth approximately $40,000. Virtu Financial LLC bought a new stake in Histogen during the 2nd quarter worth approximately $69,000. Finally, Meitav Dash Investments Ltd. grew its position in Histogen by 67.6% during the 2nd quarter. Meitav Dash Investments Ltd. now owns 124,000 shares of the company’s stock worth $135,000 after acquiring an additional 50,000 shares during the last quarter. Institutional investors own 6.81% of the company’s stock.
Separately, Zacks Investment Research upgraded Histogen from a “sell” rating to a “hold” rating in a research note on Wednesday.
Histogen (NASDAQ:HSTO) last released its quarterly earnings data on Wednesday, November 10th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Histogen had a negative return on equity of 84.22% and a negative net margin of 1,018.14%. The company had revenue of $0.59 million for the quarter. During the same quarter in the prior year, the company posted ($0.27) earnings per share. On average, equities research analysts expect that Histogen will post -0.43 earnings per share for the current fiscal year.
Histogen, Inc engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. It focuses in Human Multipotent Cell Conditioned Media, Human Extracellular Matrix, and Hair Stimulating Complex. The company was founded by Steven J.
See Also: Quantitative Easing
Receive News & Ratings for Histogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogen and related companies with MarketBeat.com's FREE daily email newsletter.